- Poster presentation
- Open Access
Adenosine cardiac magnetic resonance: follow-up of patients with very high cardiovascular risk
© Esteban-Fernández et al; licensee BioMed Central Ltd. 2015
- Published: 3 February 2015
- Diabetes Mellitus
- Myocardial Infarction
- Cardiovascular Risk
- Acute Coronary Syndrome
Stress cardiac magnetic resonance with adenosine (CMR-A) is a valid test to rule out myocardial ischaemia. We follow-up a cohort of patients with CMR-A due to suspected myocardial ischaemia, considering patients with very high cardiovascular risk.
We included all patients with CMR-A between June 2009 and November 2012, considering two groups: those with a very high cardiovascular risk (prior myocardial infarction or/and Diabetes mellitus) and the rest of the patients. The follow-up was done in outpatient cardiology clinic or by phone. We analyse free-event survival considering: acute coronary syndrome (ACS), death for any cause, admission for heart failure (HF) or necessity of revascularization as endpoints. The statistical analysis was made with SPSS 20.0.
Characteristics of the patients with CMR-A to rule out myocardial ischaemia considering cardiovascular risk
High cardiovascular risk (n=134)
Non-high cardiovascular risk (n=105)
Diabetes mellitus-no (%)
Basal glucose (mg/dL)
No tobacco history-no (%)
Arterial hypertension-no (%)
Previous ictus-no (%)
Peripheral arterial disease-no (%)
Previous myocardial infarction-no (%)
PCI revascularization-no (%)
CABG revascularization-no (%)
Result in CMR-A
Events in follow-up-no (%)
Death for any cause-no (%)
Admission for HF-no (%)
CMR-A was positive for myocardial ischaemia in 83 patients (35%) and negative in 156 (65%). The follow-up median was 25 months, with events in 68 patients. The results of the test and the events during the follow-up in each group are attached in table 1.
In this cohort of patients with very high cardiovascular risk, those with a negative result have fewer events in the follow-up. CMR-A allows a better classification of the global cardiovascular risk
There is not any funding to support this trial.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.